Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jun 13, 2023 12:27pm
85 Views
Post# 35493925

RE:RE:RE:RE:RE:RE:Very encouraging, but approval will take time

RE:RE:RE:RE:RE:RE:Very encouraging, but approval will take timeI don't think they mentioned the path to approval is SD even so having extended period of stable disease among heavily treated patients is impressive. The eye toxicity seems to be manageable by prophylactics the nerv issue based on Dr. Merci's past experience and as per Christian's comments(pre clinical observations) is supposed to be dealt with based on lower and more frequently dosing this time also based on body weight rather than surface maybe because cancer patients loose weight because of cancer itself and treatments so they can get that tolerable dose more confidently and accurately?!
Again a lot of info during a rather short time, they could do with a longer call in my opinion rather than rushing through questions. Nothing about the timing, funding and very little about partnership if any. My impression is they are hopeful/more positive about getting efficacy but worried about toxicity issues as it seems the new design has bits added to it to deal with the issue..,
<< Previous
Bullboard Posts
Next >>